Aurora Cannabis Inc. Common Shares ACB

Aurora Cannabis Inc es una empresa canadiense de cannabis medicinal. Las principales líneas estratégicas de negocio de la empresa se centran en la producción, distribución y venta de cannabis en Canadá e internacionalmente. La empresa se enfoca en ofrecer sus productos de cannabis al mercado global de cannabis medicinal, al mercado de consumo de cannabis y a los mercados globales de cannabidiol (CBD) derivado del cáñamo. La empresa ofrece variedades de productos infusionados con cannabis bajo diversas marcas que incluyen Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler y ROAR Sports. Su cartera de productos incluye cannabis seco, aceite de cannabis, cápsulas blandas, tiras orales disolventes, comestibles, vaporizadores y chocolates infusionados con cannabis.

ACB hizo una agrupación de acciones (split inverso) de 1:10 el 20 de febrero de 2024: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• The Motley Fool 26 sept

  Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.

  Curaleaf launched a hostile takeover bid for Aurora Cannabis at $4 per share in August 2026, which Aurora rejected as undervalued. The situation has escalated with Curaleaf attempting to block Aurora's ability to raise capital through stock sales. With the tender offer open until December 1, significant animosity between the companies makes integration difficult if the acquisition succeeds, while Aurora shareholders face uncertainty about whether to accept the offer or hold for potential higher valuations.

  

• The Motley Fool 15 sept

  Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

  Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

  

• The Motley Fool 5 sept

  Should You Buy Canopy Growth Stock on the Rebound?

  Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

  

• The Motley Fool 28 ago

  Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

  Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.

  

• The Motley Fool 23 ago

  The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.

  Curaleaf initiated a takeover bid for Aurora Cannabis, signaling an M&A wave in the cannabis sector following expected federal rescheduling from Schedule I to Schedule III. Green Thumb Industries, a profitable multi-state operator, has the financial capacity to pursue acquisitions but is likely to favor disciplined, smaller bolt-on deals in limited-license states over aggressive megamergers, prioritizing share buybacks and organic growth.